Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas

CONCLUSIONSThese results from the largest sample size suggest that EGFR‐TKI therapy is effective in patients with Del‐19+21L858R mutations, Del‐19/21L858R+atypical mutations, and double atypical mutations but is less effective in patients with a primary drug‐resistant pattern. Patients with the Del‐19+21L858R mutations may, therefore, benefit more from treatment with first‐generation TKIs. Cancer 2018. © 2018 American Cancer Society.

Source: Cancer - March 15, 2018 Category: Cancer & Oncology Authors: Bo Zhang, Shuyuan Wang, Jie Qian, Wenjia Yang, Fangfei Qian, Jun Lu, Yanwei Zhang, Rong Qiao, Baohui Han Tags: Original Article Source Type: research